Redefining robotic image-guidance – tomographic visualization of lesions during prostate cancer surgery via gantry-free robotic SPECT
Abstract Purpose The introduction of the drop-in gamma probe has advanced intraoperative molecular imaging during prostate cancer surgery. We have been able to convert the sensor’s numeric readout to tomographic images, so-called robotic-SPECT ( Robo SPECT) and investigate how this is impacted by radiopharmaceutical avidities and drop-in scan metrics. Methods The gamma sensor readout was registered with its 3D position and orientation, allowing a custom reconstruction algorithm to generate Robo SPECT images. Evaluations occurred in 21 patients; 10 sentinel node procedures (SN; primary prostate cancer) and 11 PSMA-radioguided surgery (recurrent prostate cancer). Robo SPECT findings were related to respective pre- and intra-operative controls, including preoperative PSMA-PET/CT and/or SPECT/CT images and fluorescence detection (SN only). Results Robo SPECT proved to be safe and applicable in a range of conditions. In the SN-group, 26 SN-SPECT/CT lesions were successfully identified with SN- Robo SPECT (100%); 3 were tumor positive (sensitivity 100%). Only 73% of SNs were surgically visible with fluorescence imaging. For the PSMA guided group, the 14 lesions identified on PSMA-PET/CT were all visualized with PSMA- Robo SPECT (100%); 18 specimens were tumor positive (sensitivity 78% for both PSMA-PET/CT and PSMA- Robo SPECT). Preoperative PSMA-SPECT/CT only identified 4 PSMA-lesions (29%). No false positives were seen for robo SPECT and all final resection margins were clean. At 6-months 0% of the SN-patients and 20% of PSMA-patients showed biochemical recurrence. Conclusion Robo SPECT provides 3D context that extends the utility of drop-in gamma tracing and assists the alignment between pre- and intra-operative target perception. Here SN- Robo SPECT clearly outperformed fluorescence SN imaging and PSMA- Robo SPECT outperformed preoperative PSMA-SPECT/CT imaging.
Authors
- Thomas Wendler (ORCID: https://orcid.org/0000-0002-0915-0510)
- Henk G. van der Poel (ORCID: https://orcid.org/0000-0002-8772-1120)
- Matthias N. van Oosterom (ORCID: https://orcid.org/0000-0003-0306-2568)
- Anne‐Claire Berrens (ORCID: https://orcid.org/0000-0002-3328-384X)
- Samaneh Azargoshasb (ORCID: https://orcid.org/0000-0001-6136-8835)
- E.M.K. Wit
- Pim J. van Leeuwen (ORCID: https://orcid.org/0000-0002-9598-5345)
- M. Sinaasappel
- L. J. Slof
- F. W. B. van Leeuwen
- K. Pirkovets
- B. A. Cakal (ORCID: https://orcid.org/0009-0009-2807-1103)
Institutions
- Technische Hochschule Augsburg (DE)
- University of Augsburg (DE)
- Leiden University Medical Center (NL)
- University Hospital Augsburg (DE)
- The Netherlands Cancer Institute (NL)
- Holoeye Photonics (Germany) (DE)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1007/s00259-026-07987-z
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Stichting voor de Technische Wetenschappen